Abiranamo 250 mg (Abiraterone Acetate): Targeted Suppression of Androgen Synthesis in Metastatic Prostate Cancer

Prostate cancer ranks among the most prevalent oncological diseases in men. In its advanced stages, when the tumor ceases to respond to conventional hormonal manipulation and enters the castration-resistant phase, the clinician’s armamentarium narrows to agents capable of intervening at the deepest levels of androgen biosynthesis. Abiranamo 250 mg is an Indian generic of the original abiraterone acetate, manufactured by Shivnaam Tradelink LLP. Each pack holds 120 oval, biconvex tablets — at the standard daily dose of 1 gram (4 tablets), this provides exactly 30 days of uninterrupted therapy. The generic nature of the product renders this life-sustaining treatment financially accessible to a far broader circle of patients while preserving full therapeutic equivalence to the originator molecule.

🧬 Biochemical Rationale: Attacking Androgen Synthesis Beyond the Testes

The defining hallmark of castration-resistant prostate cancer (CRPC) is the tumor’s capacity to sustain its growth despite pharmacologically or surgically suppressed testicular testosterone. The mechanism lies in the ability of the neoplastic tissue itself, as well as the adrenal glands, to synthesize androgens de novo from cholesterol.

At the center of this pathological cascade stands the enzyme CYP17A1 (17α-hydroxylase/17,20-lyase). It catalyzes two sequential reactions that are critically indispensable for the production of testosterone and other androgens:

1. The 17α-hydroxylation of pregnenolone and progesterone.
2. The scission of the C17–C20 bond to generate dehydroepiandrosterone (DHEA) and androstenedione.

Abiraterone acetate is a potent and irreversible inhibitor of CYP17A1. By blocking this enzyme, it severs the entire androgen synthesis cascade — not merely within the testes (already suppressed by standard therapy), but, critically, within the adrenals and the tumor microenvironment itself. The consequence is a reduction in testosterone concentration to levels markedly lower than those achieved by conventional castration — a state oncologists designate as «deep androgen deprivation».

Deprived of its hormonal fuel, the tumor halts its proliferation and succumbs to apoptosis — a process clinically manifested as a deceleration of disease progression, regression of metastatic deposits, and prolongation of overall survival.

📋 Indication and Clinical Context

Abiranamo is prescribed strictly for:

• Metastatic Castration-Resistant Prostate Cancer (mCRPC) — a state in which the tumor progresses despite serum testosterone levels below the castration threshold (less than 50 ng/dL, and by contemporary criteria, less than 20 ng/dL).

The drug is employed in patients who have exhausted the possibilities of standard hormonal therapy (LHRH agonists, LHRH antagonists, antiandrogens) and who have typically either received prior docetaxel-based chemotherapy or have been deemed unsuitable candidates for chemotherapeutic treatment.

💊 Dosing Regimen: Precision and Discipline

• Daily Dose: 1000 mg (four 250 mg tablets) as a single administration.
• Concomitant Prednisolone: A mandatory component of therapy is the concurrent intake of low-dose prednisolone (usually 5 mg twice daily). This measure is essential to counteract the mineralocorticoid adverse effects provoked by the compensatory rise in ACTH and the consequent accumulation of mineralocorticoid precursors (deoxycorticosterone).
• Food Timing: This is among the most critically important aspects of administration. The tablets must be taken either one hour before a meal, or no sooner than two hours after eating. Concomitant intake with food, particularly a fatty meal, can multiply the absorption of abiraterone many-fold (up to 10 times), precipitating unpredictable toxicity. The tablets are swallowed whole, never chewed or crushed, with a full glass of clean water.
• Missed Dose: Should a dose be omitted, the standard four-tablet dose is taken the following day. Doubling the dose is categorically forbidden.

⚠️ Contraindications and Precautionary Measures

Abiranamo is absolutely contraindicated in:

• Women. The drug is not intended for use by females. Should the patient’s sexual partner be pregnant or capable of becoming pregnant, barrier contraception is mandatory throughout the treatment course and for a period of three months following its completion.
• Children and adolescents (minors).
• Patients with severe hepatic impairment — regular monitoring of transaminases and bilirubin is imperative. Should hepatotoxicity develop, the dose is reduced or treatment is temporarily withheld.
• Patients with severe renal impairment.
• Patients who have recently sustained a myocardial infarction or who have unstable cardiovascular pathology.

Conditions Demanding Heightened Caution:

• Arterial hypertension (risk of exacerbation due to mineralocorticoid-driven effects).
• Lactose intolerance (the tablets contain lactose).
• A history of adrenal insufficiency.

📊 Therapy Monitoring

Throughout the entire treatment course, the following parameters require regular surveillance:

• Hepatic transaminase levels (ALT, AST) — at baseline, every 2 weeks for the first 3 months, and monthly thereafter.
• Blood pressure.
• Serum potassium levels (hypokalemia risk).
• Prostate-Specific Antigen (PSA) levels, as a marker of therapeutic response.

📦 Storage

The tablets must be stored in the original packaging, in a dry environment protected from both light and moisture, at room temperature. Access by children must be entirely precluded.